• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Receptor tyrosine kinases: role in cancer progression.

作者信息

Sangwan V, Park M

机构信息

Molecular Oncology Group, McGill University Health Centre, Montreal, Quebec.

出版信息

Curr Oncol. 2006 Oct;13(5):191-3. doi: 10.3390/curroncol13050019.

DOI:10.3390/curroncol13050019
PMID:22792017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3394603/
Abstract
摘要

相似文献

1
Receptor tyrosine kinases: role in cancer progression.受体酪氨酸激酶：在癌症进展中的作用
Curr Oncol. 2006 Oct;13(5):191-3. doi: 10.3390/curroncol13050019.
2
Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia.蛋白质酪氨酸激酶：它们在白血病中的作用及靶向治疗
Cancers (Basel). 2021 Jan 7;13(2):184. doi: 10.3390/cancers13020184.
3
Role of tyrosine kinases in bladder cancer progression: an overview.酪氨酸激酶在膀胱癌进展中的作用：概述。
Cell Commun Signal. 2020 Aug 14;18(1):127. doi: 10.1186/s12964-020-00625-7.
4
Targeting tyrosine kinases and autophagy in prostate cancer.靶向治疗前列腺癌中的酪氨酸激酶和自噬。
Horm Cancer. 2011 Feb;2(1):38-46. doi: 10.1007/s12672-010-0053-3. Epub 2010 Dec 2.
5
Kinome Array Profiling of Patient-Derived Pancreatic Ductal Adenocarcinoma Identifies Differentially Active Protein Tyrosine Kinases.基于患者衍生胰腺导管腺癌的激酶组芯片分析鉴定出差异激活的蛋白酪氨酸激酶。
Int J Mol Sci. 2020 Nov 17;21(22):8679. doi: 10.3390/ijms21228679.
6
Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.联合抑制AXL、Lyn和p130Cas激酶可阻断三阴性乳腺癌细胞的迁移。
Cancer Biol Ther. 2014;15(11):1571-82. doi: 10.4161/15384047.2014.956634.
7
Recent Advances in the Role of Discoidin Domain Receptor Tyrosine Kinase 1 and Discoidin Domain Receptor Tyrosine Kinase 2 in Breast and Ovarian Cancer.盘状结构域受体酪氨酸激酶1和盘状结构域受体酪氨酸激酶2在乳腺癌和卵巢癌中作用的最新进展
Front Cell Dev Biol. 2021 Nov 3;9:747314. doi: 10.3389/fcell.2021.747314. eCollection 2021.
8
Calix[6]arene bypasses human pancreatic cancer aggressiveness: downregulation of receptor tyrosine kinases and induction of cell death by reticulum stress and autophagy.杯[6]芳烃可抑制人胰腺癌的侵袭性：下调受体酪氨酸激酶并通过内质网应激和自噬诱导细胞死亡。
Biochim Biophys Acta. 2013 Dec;1833(12):2856-2865. doi: 10.1016/j.bbamcr.2013.07.010. Epub 2013 Jul 19.
9
Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance.非受体酪氨酸激酶：它们在肿瘤进展和耐药中的结构及机制作用
Cancers (Basel). 2024 Aug 2;16(15):2754. doi: 10.3390/cancers16152754.
10
Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis.酪氨酸激酶抑制剂（TKIs）在肺癌治疗中的应用：全面分析。
Curr Cancer Drug Targets. 2021;21(1):55-69. doi: 10.2174/1568009620666201009130008.

引用本文的文献

1
Biologics, Immunotherapies, and Cytotoxic Chemotherapy for Hepatocellular Carcinoma following Current Recommendations by the BCLC: A Review of Agents.根据巴塞罗那临床肝癌（BCLC）当前推荐意见，用于肝细胞癌的生物制剂、免疫疗法和细胞毒性化疗：药物综述
Semin Intervent Radiol. 2024 Mar 14;41(1):84-91. doi: 10.1055/s-0043-1778660. eCollection 2024 Feb.
2
Role of m6A modification in regulating the PI3K/AKT signaling pathway in cancer.m6A 修饰在调控癌症中 PI3K/AKT 信号通路中的作用。
J Transl Med. 2023 Nov 1;21(1):774. doi: 10.1186/s12967-023-04651-0.
3
A multiscale cell-based model of tumor growth for chemotherapy assessment and tumor-targeted therapy through a 3D computational approach.一种基于多尺度细胞的肿瘤生长模型，通过 3D 计算方法进行化疗评估和肿瘤靶向治疗。
Cell Prolif. 2022 Mar;55(3):e13187. doi: 10.1111/cpr.13187. Epub 2022 Feb 7.
4
Differential Receptor Tyrosine Kinase Phosphorylation in the Uterus of Rats Following Developmental Exposure to Tetrabromobisphenol A.发育过程中暴露于四溴双酚A的大鼠子宫中受体酪氨酸激酶的磷酸化差异
Toxicol Res Appl. 2021 Jan-Dec;5. doi: 10.1177/23978473211047164. Epub 2021 Nov 18.
5
Activation of neurotrophin signalling with light‑inducible receptor tyrosine kinases.用光诱导的受体酪氨酸激酶激活神经营养因子信号通路。
Mol Med Rep. 2022 Feb;25(2). doi: 10.3892/mmr.2022.12586. Epub 2022 Jan 11.
6
Targeting PI3K/Akt signal transduction for cancer therapy.针对 PI3K/Akt 信号转导通路的癌症治疗策略。
Signal Transduct Target Ther. 2021 Dec 16;6(1):425. doi: 10.1038/s41392-021-00828-5.
7
[Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].[RET融合阳性晚期非小细胞肺癌的治疗进展]
Zhongguo Fei Ai Za Zhi. 2021 Dec 20;24(12):853-861. doi: 10.3779/j.issn.1009-3419.2021.101.43. Epub 2021 Nov 8.
8
Protein Tyrosine Phosphatases: A new paradigm in an old signaling system?蛋白酪氨酸磷酸酶：旧信号系统中的新范例？
Adv Cancer Res. 2021;152:263-303. doi: 10.1016/bs.acr.2021.06.001. Epub 2021 Jul 8.
9
An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC).一种基于免疫的风险分层系统，用于预测肺肉瘤样癌（PSC）的预后。
Oncoimmunology. 2021 Jul 13;10(1):1947665. doi: 10.1080/2162402X.2021.1947665. eCollection 2021.
10
Multiscale modeling of tumor growth and angiogenesis: Evaluation of tumor-targeted therapy.肿瘤生长和血管生成的多尺度建模：肿瘤靶向治疗的评估。
PLoS Comput Biol. 2021 Jun 23;17(6):e1009081. doi: 10.1371/journal.pcbi.1009081. eCollection 2021 Jun.

本文引用的文献

1
Targeting tyrosine kinases in cancer: the second wave.靶向癌症中的酪氨酸激酶：第二波。
Science. 2006 May 26;312(5777):1175-8. doi: 10.1126/science.1125951.
2
Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.巨噬细胞：肿瘤细胞迁移、侵袭和转移的必要伙伴。
Cell. 2006 Jan 27;124(2):263-6. doi: 10.1016/j.cell.2006.01.007.
3
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.曲妥珠单抗联合辅助化疗用于可手术的HER2阳性乳腺癌
N Engl J Med. 2005 Oct 20;353(16):1673-84. doi: 10.1056/NEJMoa052122.
4
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.HER2阳性乳腺癌辅助化疗后使用曲妥珠单抗。
N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306.
5
Protein phosphorylation in signaling--50 years and counting.信号转导中的蛋白质磷酸化——50年仍在继续。
Trends Biochem Sci. 2005 Jun;30(6):286-90. doi: 10.1016/j.tibs.2005.04.013.
6
Defective downregulation of receptor tyrosine kinases in cancer.癌症中受体酪氨酸激酶的下调缺陷。
EMBO J. 2004 Jul 21;23(14):2707-12. doi: 10.1038/sj.emboj.7600292. Epub 2004 Jul 1.
7
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.肺癌中的表皮生长因子受体（EGFR）突变：与吉非替尼治疗临床反应的相关性
Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29.
8
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.转移性胃肠道间质瘤患者的激酶突变与伊马替尼反应
J Clin Oncol. 2003 Dec 1;21(23):4342-9. doi: 10.1200/JCO.2003.04.190.
9
Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases.逃避Cbl介导的下调：受体酪氨酸激酶致癌性失调的一个反复出现的主题。
Cancer Cell. 2003 Jun;3(6):519-23. doi: 10.1016/s1535-6108(03)00136-3.
10
Role of receptor tyrosine kinases in lung cancer.
Methods Mol Med. 2003;74:113-25. doi: 10.1385/1-59259-323-2:113.